440 mg Trastuzumab Injection

Get a Price/Quote

MOQ : 100 Packs

440 mg Trastuzumab Injection Specification

Salt Composition
Trastuzumab 440 mg

Indication
HER2-positive breast cancer and HER2-positive metastatic gastric cancer

Dosage Form
Lyophilized Powder for Injection

Feature
Monoclonal antibody therapy targeting HER2

Ingredients
Trastuzumab (active), excipients including histidine, trehalose, polysorbate 20

Application
Intravenous injection after reconstitution

Ph Level
6.0 0.2

Physical Color/Texture
White to pale yellow lyophilized powder

Fermentation Smell
Odorless

Storage Instructions
Store at 2C to 8C (Refrigerated). Do not freeze.

Shelf Life
24 months from manufacturing date

Use in Pregnancy/Lactation
Not recommended unless clearly needed

Molecular Weight
~148 kDa

Use in Pediatrics
Safety and efficacy not established in children

Compatibility
Do not mix with dextrose-containing solutions

Appearance after Reconstitution
Clear to slightly opalescent, colorless to pale yellow solution

Administration Route
Intravenous drip (IV infusion)

Reconstitution Volume
Reconstitute with 20 mL bacteriostatic water for injection

Dilution
Further dilute reconstituted solution in 250 mL of sodium chloride 0.9% for infusion

Cautions
Monitor cardiac function during therapy

Pack Size
One 20 mL vial containing 440 mg trastuzumab with 20 mL bacteriostatic water for injection

Contraindications
Hypersensitivity to trastuzumab or any excipients

Target
Human Epidermal Growth Factor Receptor 2 (HER2/neu)

Prescription Status
Prescription only

440 mg Trastuzumab Injection Trade Information

Minimum Order Quantity
100 Packs

Payment Terms
Cash in Advance (CID)

Supply Ability
5000 Packs Per Month

Delivery Time
2-10 Days

Main Domestic Market
All India

About 440 mg Trastuzumab Injection

Introducing our 440 mg Trastuzumab Injection, a stellar anti-cancer solution designed for HER2-positive breast and metastatic gastric cancers. Each pack provides a 20 mL vial containing reduced-price trastuzumab, conveniently supplied with bacteriostatic water for injection. The product guarantees radiant efficacy through intravenous infusion, ensuring compatibility and excellent purity with a clear, colorless to pale yellow solution post-reconstitution. With restricted access for prescription-only use, this lyophilized powder offers an excellent discount for bulk orders from trusted suppliers in India, while supporting vigilant cardiac monitoring for patient safety.

Focused Therapeutic Applications for Oncology Care

440 mg Trastuzumab Injection is clinically indicated for the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric cancer. Specifically formulated for intravenous reconstitution and infusion, this monoclonal antibody provides targeted therapy in hospital and oncology clinic settings. Its radiant effect as a targeted agent offers substantial benefits for both general and specific oncologic uses, supporting a wide commercial reach among healthcare facilities and medical professionals across the globe.

Flexible Payment, Packing, and Export Advantages

Benefit from stellar sale prices and discount offers for bulk procurement of the 440 mg Trastuzumab Injection. Secure shipping is ensured, with excellent packing and timely dispatch to protect the product's integrity during transit. Payment terms are designed for ease and flexibility, adapting to both domestic and international clients. Samples can be accessed upon request, supporting confident evaluation by purchasers in main export markets worldwide, including Europe, Asia, Africa, and the Americas.

FAQ's of 440 mg Trastuzumab Injection:

Q: How should the 440 mg Trastuzumab Injection be prepared and administered?

A: The vial should be reconstituted with 20 mL of bacteriostatic water for injection, and then the clear solution should be further diluted in 250 mL of 0.9% sodium chloride before being administered as an intravenous infusion.

Q: What are the primary therapeutic benefits of Trastuzumab Injection?

A: Trastuzumab Injection offers excellent therapeutic outcomes for patients with HER2-positive breast cancer and HER2-positive metastatic gastric cancer, providing targeted monoclonal antibody therapy to inhibit tumor growth.

Q: When is this product contraindicated?

A: Use is contraindicated in individuals with hypersensitivity to trastuzumab or any of its excipients. Cardiac function should be monitored during therapy, and use in pregnancy and lactation is not recommended unless clearly needed.

Q: Where can this product be supplied or exported from?

A: This product is supplied and exported from India, with main export markets including Europe, Asia, Africa, and the Americas, ensuring access to quality oncology therapeutics globally.

Q: What is the process for secure shipping and packaging?

A: Orders are carefully packed and dispatched under controlled refrigerated conditions (2C to 8C), maintaining product stability and safety during international and local shipment.

Q: How can buyers benefit from the available sale price and discounts?

A: Buyers can enjoy reduced prices and excellent discount offers, especially for bulk purchases, making this therapy more accessible for large healthcare providers and distributors.

Tell us about your requirement